Impact of late toxicities on quality of life for survivors of nasopharyngeal carcinoma

BMC Cancer

Table 4 The GLM-MANOVA model of the effects of the CTCAE scales on the fifteen EORTC QLQ-C30 scales

EORTC QLQ-C30
	One-factor model*		Multifactor model**
Variable	Wilk’s λ	P value	Wilk’s λ	P value
Clinical variable
Age (≦40 v 41–60 v >60)	0.844	0.177	0.878	NS
Gender (Male v Female)	0.891	0.048	0.881	NS
Education years (≦6 yrs v 6-12 yrs v >12 yrs)	0.779	0.004	0.766	0.003
Marital status (Without v with partner)	0.922	0.285	--	--
AJCC stage (I v II v III v IV)	0.765	0.088	0.876	NS
Radiotherapy technique (Non-IMRT v IMRT)	0.806	<0.001	0.739	0.002
Chemotherapy (No v Yes)	0.894	0.058	0.957	NS
Survival years (5 ~ 7 yrs v 7-10 yrs v >10 yrs)	0.795	0.012	0.795	0.021
CTCAE
Neuropathy (0 v 1 v 2 v 3)	0.650	<0.001	0.686	0.001
Hearing loss (0 v 1 v 2 v 3 + 4)	0.658	<0.001	0.713	0.02
Dysphagia (0 v 1 v 2 v 3)	0.702	0.002	0.755	NS
Xerostomia (0 v 1 v 2 v 3)	0.631	<0.001	0.697	0.003
Neck (0 v 1 v 2 + 3)	0.782	0.006	0.853	NS

GLM-MANOVA: general linear model multivariate analysis of variance; EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30; CTCAE: Common Terminology Criteria for Adverse Events, v4.0; AJCC: American Joint of Cancer Committee published in 2002; IMRT: intensity modulated radiotherapy; NS: not significant; *The one factor model: only one independent variable was entered into the model; **The multifactor model: variables with p < 0.25 in one-factor model were entered as independent variables in the model (Backward exclusion).

ISSN: 1471-2407